$11.69
1.93% today
Nasdaq, Aug 25, 08:19 pm CET
ISIN
BMG762791017
Symbol
ROIV

Roivant Sciences Target price 2025 - Analyst rating & recommendation

Roivant Sciences Classifications & Recommendation:

Buy
88%
Hold
12%

Roivant Sciences Price Target

Target Price $17.85
Price $11.92
Potential
Number of Estimates 11
11 Analysts have issued a price target Roivant Sciences 2026 . The average Roivant Sciences target price is $17.85. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 17 analysts: 15 Analysts recommend Roivant Sciences to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Roivant Sciences stock has an average upside potential 2026 of . Most analysts recommend the Roivant Sciences stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '25 2026
Estimates
Revenue Million $ 29.05 25.75
11.19% 11.37%
EBITDA Margin -3,785.23% -5,006.77%
54.21% 32.27%
Net Margin -592.01% -3,827.70%
104.45% 546.56%

11 Analysts have issued a sales forecast Roivant Sciences 2026 . The average Roivant Sciences sales estimate is

$25.7m
Unlock
. This is
11.37% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$49.6m 70.60%
Unlock
, the lowest is
$9.1m 68.67%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $29.1m 11.19%
2026
$25.7m 11.37%
Unlock
2027
$98.1m 281.14%
Unlock
2028
$598m 509.04%
Unlock
2029
$1.2b 108.81%
Unlock
2030
$2.2b 73.08%
Unlock
2031
$3.2b 46.16%
Unlock
2032
$4.8b 51.12%
Unlock

5 Analysts have issued an Roivant Sciences EBITDA forecast 2026. The average Roivant Sciences EBITDA estimate is

$-1.3b
Unlock
. This is
17.23% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-1.2b 10.00%
Unlock
, the lowest is
$-1.4b 29.76%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $-1.1b 36.96%
2026
$-1.3b 17.23%
Unlock
2027
$-915m 28.99%
Unlock
2028
$-756m 17.37%
Unlock

EBITDA Margin

2025 -3,785.23% 54.21%
2026
-5,006.77% 32.27%
Unlock
2027
-932.83% 81.37%
Unlock
2028
-126.57% 86.43%
Unlock

11 Roivant Sciences Analysts have issued a net profit forecast 2026. The average Roivant Sciences net profit estimate is

$-986m
Unlock
. This is
473.04% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-862m 401.38%
Unlock
, the lowest is
$-1.4b 701.07%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $-172m 103.95%
2026
$-986m 473.04%
Unlock
2027
$-950m 3.60%
Unlock
2028
$-606m 36.24%
Unlock
2029
$-49.7m 91.80%
Unlock
2030
$394m 892.86%
Unlock
2031
$912m 131.53%
Unlock
2032
$1.8b 99.22%
Unlock

Net Margin

2025 -592.01% 104.45%
2026
-3,827.70% 546.56%
Unlock
2027
-968.12% 74.71%
Unlock
2028
-101.35% 89.53%
Unlock
2029
-3.98% 96.07%
Unlock
2030
18.24% 558.29%
Unlock
2031
28.89% 58.39%
Unlock
2032
38.09% 31.84%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Mar '25 2026
Estimates
Earnings Per Share $ -0.23 -1.42
104.40% 517.39%
P/E negative
EV/Sales 126.35

11 Analysts have issued a Roivant Sciences forecast for earnings per share. The average Roivant Sciences EPS is

$-1.42
Unlock
. This is
491.67% lower
Unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-1.24 416.67%
Unlock
, the lowest is
$-1.98 725.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-0.23 104.40%
2026
$-1.42 517.39%
Unlock
2027
$-1.37 3.52%
Unlock
2028
$-0.87 36.50%
Unlock
2029
$-0.07 91.95%
Unlock
2030
$0.57 914.29%
Unlock
2031
$1.31 129.82%
Unlock
2032
$2.61 99.24%
Unlock

P/E ratio

Current -49.67 2,953.92%
2026
-8.42 83.05%
Unlock
2027
-8.73 3.68%
Unlock
2028
-13.69 56.82%
Unlock
2029
-166.95 1,119.50%
Unlock
2030
21.06 112.61%
Unlock
2031
9.09 56.84%
Unlock
2032
4.56 49.83%
Unlock

Based on analysts' sales estimates for 2026, the Roivant Sciences stock is valued at an EV/Sales of

126.35
Unlock
and an P/S ratio of
316.15
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 111.98 326.27%
2026
126.35 12.83%
Unlock
2027
33.15 73.76%
Unlock
2028
5.44 83.58%
Unlock
2029
2.61 52.11%
Unlock
2030
1.51 42.22%
Unlock
2031
1.03 31.58%
Unlock
2032
0.68 33.83%
Unlock

P/S ratio

Current 280.20 276.39%
2026
316.15 12.83%
Unlock
2027
82.95 73.76%
Unlock
2028
13.62 83.58%
Unlock
2029
6.52 52.11%
Unlock
2030
3.77 42.22%
Unlock
2031
2.58 31.58%
Unlock
2032
1.71 33.83%
Unlock

Current Roivant Sciences Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Jun 18 2025
HC Wainwright & Co.
Locked
Locked
Locked May 28 2025
HC Wainwright & Co.
Locked
Locked
Locked Apr 21 2025
HC Wainwright & Co.
Locked
Locked
Locked Feb 11 2025
HC Wainwright & Co.
Locked
Locked
Locked Nov 13 2024
Cantor Fitzgerald
Locked
Locked
Locked Sep 19 2024
HC Wainwright & Co.
Locked
Locked
Locked Sep 19 2024
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Jun 18 2025
Locked
HC Wainwright & Co.:
Locked
Locked
May 28 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 21 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 11 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Nov 13 2024
Locked
Cantor Fitzgerald:
Locked
Locked
Sep 19 2024
Locked
HC Wainwright & Co.:
Locked
Locked
Sep 19 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today